Founded in 2020, Alithea Genomics SA is a rapidly growing provider of high-throughput RNA-seq services, kits and bioinformatics solutions. With its flagship technology based on early sample barcoding and pooling, the startup has developed the MERCURIUS BRB-seq kit, which right after the initial reverse transcription reaction allows for the processing of hundreds of RNA samples in one single tube. This translates into a significant reduction of reagents and manual effort involved in the overall workflow. The MERCURIUS BRB-seq kits provide an optimized set of barcodes, ensuring uniform and reproducible data generation from many samples.
Moreover, the newly launched BRB-seq kits are also optimized for RNA samples from various tissue types. In addition to standard purified RNA, they are also compatible with cell lysates (eliminating the need for RNA extraction) and blood RNA samples (globin depletion is integrated into the BRB-seq workflow).
“We are particularly proud of our first kits, especially after a successful beta-testing period with early adopters,” said Daniel Alpern, CTO at Alithea Genomics. “BRB-seq has already proved itself an empowering solution for several users, and now, through our kits, we want to make it easy and convenient for anyone to adopt this new technology”.
The company is first entering the North American and European markets. Its plans to reach the Asian and wider EMEA markets are underway, as revealed by Riccardo Dainese, CEO of Alithea Genomics. With funding from the newly launched seed round, the startup plans to strengthen its IP portfolio further, bring the next-gen kits to the market, and scale operations.
(Press release/RAN)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines